We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors’ focus to be on the progress of Vaxart, Inc.’s (VXRT - Free Report) coronavirus vaccine program when the company reports second-quarter 2020 results. In the last reported quarter, the company delivered an earnings surprise of 50.00%.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and met the same once, with the average surprise being 20.78%.
Vaxart’s share price has surged 3066.9% so far this year against the industry’s decrease of 6.9%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Vaxart has one royalty-bearing product in its portfolio — Inavir. The drug is an antiviral for the treatment of influenza that is marketed by GlaxoSmithKline (GSK - Free Report) . Vaxart earns royalty on net sales of the drug in Japan. However, we note that sales of this antiviral varies significantly from quarter to quarter due to the seasonality and intensity of flu. The company had another royalty-bearing product, Relenza, that lost patent protection in July 2019, following which the company did not earn any royalty on its sales.
The company has been also developing vaccine candidates for norovirus, coronavirus and influenza. The monovalent influenza vaccine is the most advanced candidate in its pipeline and is currently being evaluated in a phase II study. Norovirus vaccine candidate is in phase I stage. The company has a collaboration with J&J (JNJ - Free Report) to develop an influenza vaccine. Currently, it is in preclinical stage. Ongoing clinical studies and pre-clinical developments are likely to have driven operating expenses higher during the reporting quarter.
Vaxart has also been focusing on developing a coronavirus vaccine. The company initiated its coronavirus program in January. The company announced positive pre-clinical data in April and selected its lead candidate for a clinical study in May. The company has been developing an oral vaccine using its proprietary VAAST oral vaccines platform. In June, the vaccine became a part of the Operation Warp Speed, an initiative by the U.S. federal government to provide substantial quantities of safe, effective vaccine for Americans by January 2021. The company expects to start a phase I study to evaluate its coronavirus vaccine candidate in the second half of 2020.
We expect the company to discuss the progress of its coronavirus vaccine candidate on its second-quarter earnings call. It can also provide an update related to the timeline for initiation of a clinical study.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Vaxart this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 8 cents per share) and the Zacks Consensus Estimate (loss of 7 cents per share) is -20.00%.
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained an impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
We expect investors’ focus to be on the progress of Vaxart, Inc.’s (VXRT - Free Report) coronavirus vaccine program when the company reports second-quarter 2020 results. In the last reported quarter, the company delivered an earnings surprise of 50.00%.
The company’s earnings beat the Zacks Consensus Estimate in three of the last four quarters and met the same once, with the average surprise being 20.78%.
Vaxart’s share price has surged 3066.9% so far this year against the industry’s decrease of 6.9%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Vaxart has one royalty-bearing product in its portfolio — Inavir. The drug is an antiviral for the treatment of influenza that is marketed by GlaxoSmithKline (GSK - Free Report) . Vaxart earns royalty on net sales of the drug in Japan. However, we note that sales of this antiviral varies significantly from quarter to quarter due to the seasonality and intensity of flu. The company had another royalty-bearing product, Relenza, that lost patent protection in July 2019, following which the company did not earn any royalty on its sales.
The company has been also developing vaccine candidates for norovirus, coronavirus and influenza. The monovalent influenza vaccine is the most advanced candidate in its pipeline and is currently being evaluated in a phase II study. Norovirus vaccine candidate is in phase I stage. The company has a collaboration with J&J (JNJ - Free Report) to develop an influenza vaccine. Currently, it is in preclinical stage. Ongoing clinical studies and pre-clinical developments are likely to have driven operating expenses higher during the reporting quarter.
Vaxart has also been focusing on developing a coronavirus vaccine. The company initiated its coronavirus program in January. The company announced positive pre-clinical data in April and selected its lead candidate for a clinical study in May. The company has been developing an oral vaccine using its proprietary VAAST oral vaccines platform. In June, the vaccine became a part of the Operation Warp Speed, an initiative by the U.S. federal government to provide substantial quantities of safe, effective vaccine for Americans by January 2021. The company expects to start a phase I study to evaluate its coronavirus vaccine candidate in the second half of 2020.
We expect the company to discuss the progress of its coronavirus vaccine candidate on its second-quarter earnings call. It can also provide an update related to the timeline for initiation of a clinical study.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Vaxart this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate (loss of 8 cents per share) and the Zacks Consensus Estimate (loss of 7 cents per share) is -20.00%.
Zacks Rank: Vaxart currently has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
VAXART, INC. Price and Consensus
VAXART, INC. price-consensus-chart | VAXART, INC. Quote
A Stock That Warrants a Look
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained an impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>